MarketCap
Facebook
X
TelegramAnnual report 2025
added 02-11-2026
Bristol-Myers Squibb Company Long-Term Debt 2011-2026 | BMY
Long-term debt is a financial obligation of a company or an individual with a repayment period exceeding one year from the date it arises. In accounting, such obligations are recorded under the "long-term liabilities" section.
Main characteristics:- Term exceeds 12 months
- Can take the form of bonds, bank loans, credit lines, leasing, or loans from affiliated parties
- Repaid through regular payments (interest and/or principal) over several years
- Investment in development
Allows financing of large projects — new factories, production lines, innovative developments — without diverting working capital. - Smoothing of cash flows
A long-term payment schedule facilitates budget planning and reduces short-term financial risks. - Optimization of capital structure
A combination of equity and borrowed capital can reduce the average cost of business financing.
A high level of long-term debt may indicate that a company heavily relies on borrowed funds. This increases risks, especially in conditions of rising interest rates or declining profits. However, a moderate level of debt can signal a sound growth strategy — for example, the company takes a loan to expand its business.
If a company uses borrowed funds effectively (e.g., invests in profitable projects), this can lead to profit growth and, consequently, an increase in stock value. An investor evaluates whether the investments made using debt are paying off.
It is important to monitor whether the company can regularly pay interest and repay the principal. Payment difficulties can lead to reduced dividends, a drop in stock value, and even bankruptcy.
Examples of long-term debt:- Mortgage loans for property purchases
- Corporate bonds issued by a company to raise capital
- Project financing — long-term loans for building or expanding production facilities
- Leasing obligations for equipment or transport
Annual Long-Term Debt Bristol-Myers Squibb Company
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 42.8 B | 47.6 B | 36.7 B | 35.1 B | 39.6 B | 48.3 B | 43.4 B | 5.65 B | 6.98 B | 5.72 B | 6.55 B | 7.24 B | 7.98 B | 6.57 B | 5.38 B |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 48.3 B | 5.38 B | 23 B |
Quarterly Long-Term Debt Bristol-Myers Squibb Company
| 2025-Q2 | 2025-Q1 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 44.5 B | 46.2 B | 48.7 B | 48.9 B | 49.5 B | 32.1 B | 34.7 B | 35.1 B | 35.1 B | 37 B | - | 37.4 B | 39.6 B | 39.7 B | 42.5 B | 44.5 B | 48.3 B | 48.3 B | 48.3 B | 48.3 B | 43.4 B | 43.4 B | 43.4 B | 43.4 B | 5.65 B | 5.65 B | 5.65 B | 5.65 B | 6.98 B | 6.98 B | 6.98 B | 6.98 B | 5.72 B | 5.72 B | 5.72 B | 5.72 B | 6.55 B | 6.55 B | 6.55 B | 6.55 B | 7.24 B | 7.24 B | 7.24 B | 7.24 B | 7.98 B | 7.98 B | 7.98 B | 7.98 B | 6.57 B | 6.57 B | 6.57 B | 6.57 B | 5.38 B | 5.38 B | 5.38 B | 5.38 B |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 49.5 B | 5.38 B | 21.6 B |
Long-Term Debt of other stocks in the Biotechnology industry
| Issuer | Long-Term Debt | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
273 M | - | 2.43 % | $ 254 M |  Germany |
 |
ARCA biopharma
ABIO
|
755 K | - | 1052.0 % | $ 415 M |  USA |
 |
Aeterna Zentaris
AEZS
|
31 K | - | 5.93 % | $ 314 M |  Canada |
 |
Albireo Pharma
ALBO
|
9.62 M | - | -0.23 % | $ 916 M | USA |
 |
I-Mab
IMAB
|
68.2 M | - | - | $ 866 M |  China |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
2.42 B | - | - | $ 40.3 B | USA |
 |
Genfit SA
GNFT
|
173 M | - | 2.54 % | $ 160 B |  France |
 |
Aileron Therapeutics
ALRN
|
69 K | - | 10.36 % | $ 9.8 M | USA |
 |
Altimmune
ALT
|
34.3 M | $ 3.44 | 2.99 % | $ 303 M | USA |
 |
Biophytis SA
BPTS
|
1.83 M | - | -13.47 % | $ 169 M | France |
 |
Midatech Pharma plc
MTP
|
4.76 M | - | -18.52 % | $ 27.3 M |  Britain |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
278 K | - | -1.52 % | $ 24.7 M | USA |
 |
Amgen
AMGN
|
50 B | $ 349.77 | 0.57 % | $ 188 B | USA |
 |
Amphastar Pharmaceuticals
AMPH
|
620 M | $ 19.23 | -1.38 % | $ 899 M | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
9.12 M | - | - | $ 26.5 M | USA |
 |
Amarin Corporation plc
AMRN
|
6.08 M | $ 14.6 | 0.76 % | $ 6.06 B |  Irlanda |
 |
AgeX Therapeutics
AGE
|
13.2 M | - | -10.17 % | $ 12.2 K | USA |
 |
Acorda Therapeutics
ACOR
|
167 M | - | -24.86 % | $ 820 K | USA |
 |
Acasti Pharma
ACST
|
410 K | - | 4.01 % | $ 150 M | Canada |
 |
Институт стволовых клеток человека
ISKJ
|
175 M | - | - | - |  Russia |
 |
Inventiva S.A.
IVA
|
10 M | $ 6.08 | 5.19 % | $ 138 M | France |
 |
Adverum Biotechnologies
ADVM
|
86 M | - | - | $ 86.2 M | USA |
 |
Acer Therapeutics
ACER
|
146 K | - | 2.71 % | $ 14 M | USA |
 |
Advaxis
ADXS
|
8.14 M | - | -9.65 % | $ 45.9 M | USA |
 |
Avenue Therapeutics
ATXI
|
2.03 M | - | -52.27 % | $ 4.45 M | USA |
 |
Autolus Therapeutics plc
AUTL
|
47.9 M | $ 1.4 | 2.19 % | $ 357 M | Britain |
 |
Ayala Pharmaceuticals
AYLA
|
1.33 M | - | - | $ 7.46 M |  Israel |
 |
ChemoCentryx
CCXI
|
4.72 M | - | - | $ 3.74 B | USA |
 |
Aytu BioScience
AYTU
|
10.9 M | $ 2.63 | 0.77 % | $ 16.5 M | USA |
 |
Atreca
BCEL
|
60.3 M | - | -11.76 % | $ 5.79 M | USA |
 |
BioDelivery Sciences International
BDSI
|
78.5 M | - | -4.8 % | $ 255 M | USA |
 |
Aeglea BioTherapeutics
AGLE
|
4 M | - | - | $ 1.01 B | USA |
 |
CureVac N.V.
CVAC
|
25.4 M | - | - | $ 867 M | Germany |
 |
BeiGene, Ltd.
BGNE
|
962 M | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
Bellerophon Therapeutics
BLPH
|
203 K | - | -74.18 % | $ 955 K | USA |
 |
Benitec Biopharma
BNTC
|
495 K | $ 11.19 | 1.91 % | $ 461 M | USA |
 |
Akero Therapeutics
AKRO
|
529 K | - | - | $ 3.67 B | USA |
 |
Arbutus Biopharma Corporation
ABUS
|
806 K | $ 4.42 | 4.25 % | $ 734 M | Canada |
 |
Akouos
AKUS
|
28.3 M | - | 0.23 % | $ 488 M | USA |
 |
AIkido Pharma
AIKI
|
2.63 M | - | 1.93 % | $ 17.4 M | USA |
 |
Allakos
ALLK
|
38.2 M | - | - | $ 28.6 M | USA |
 |
Brickell Biotech
BBI
|
146 K | - | -5.38 % | $ 6.06 M | USA |
 |
Allena Pharmaceuticals
ALNA
|
210 K | - | 3.16 % | $ 1.9 M | USA |
 |
Cabaletta Bio
CABA
|
2.88 M | $ 2.82 | -4.08 % | $ 3.29 M | USA |
 |
Calithera Biosciences
CALA
|
1.67 M | - | -10.95 % | $ 876 K | USA |
 |
Alpine Immune Sciences
ALPN
|
3.38 M | - | - | $ 2.17 B | USA |
 |
Cara Therapeutics
CARA
|
6.09 M | - | -3.03 % | $ 260 M | USA |
 |
Ampio Pharmaceuticals
AMPE
|
274 K | - | -11.43 % | $ 502 K | USA |
 |
AlloVir
ALVR
|
1.13 M | - | 4.14 % | $ 49.1 M | USA |